Cell type-associated traits map for the [AdultAdrenalGland_Smooth muscle cell][link to cell ontology]. Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-04 as default, and users can change it to 1e-03, 1e-05, or 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple TAG sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below.” The association association is listed in the table at bottom, Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns).
Table. List of Cell type-associated traits pairs for [AdultAdrenalGland_Smooth muscle cell]. If the network above is too complicated. the users could obtain the association information from the table at bottom. Because each trait has multiple TAG sets defined at different thresholds, there may be multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Trait Name | Trait Full Name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|
Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 5.00e-2 | 3.70e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 5.00e-2 | 2.15e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-2 | 3.08e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-3 | 3.99e-3 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-4 | 3.76e-2 |
BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-5 | 3.41e-2 |
BMI | Body Mass Index | MTC | Speliotes | 2010 | NA | 123865 | 5.00e-2 | 2.45e-3 |
Bone Mineral Density Estimated | Bone Mineral Density Estimated | MTC | Kemp | 2017 | NA | 142487 | 1.00e-2 | 1.34e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 5.00e-2 | 1.56e-2 |
CAD | Coronary Artery Disease | MTC | Nelson | 2017 | 18467 | 45264 | 1.00e-2 | 1.08e-2 |
Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.83e-2 |
Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 5.00e-2 | 2.83e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-2 | 2.41e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.92e-2 |
Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 3.58e-2 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 2.29e-3 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 2.85e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-2 | 3.44e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-3 | 1.25e-2 |
Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 1.00e-3 | 2.58e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 5.00e-2 | 3.14e-2 |
Albuminuria | Microalbuminuria | MTC | Boger | 2011 | NA | 31580 | 1.00e-3 | 3.87e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 5.00e-2 | 1.23e-2 |
Albuminuria | Microalbuminuria | MTC | Teumer | 2016 | NA | 54116 | 1.00e-3 | 4.91e-3 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 3.52e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 2.85e-2 |
Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 4.45e-2 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 1.00e-3 | 2.99e-2 |
Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 1.00e-4 | 3.72e-2 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 5.00e-2 | 5.45e-4 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-2 | 7.28e-3 |
Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-3 | 2.46e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 6.37e-3 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 1.38e-2 |
Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-2 | 1.83e-2 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 5.00e-2 | 4.15e-3 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-2 | 3.47e-3 |
Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-3 | 1.54e-2 |
Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 1.00e-2 | 1.17e-2 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 5.00e-2 | 7.80e-3 |
Anxiety | Anxiety Dichotomous | MTC | Otowa | 2016 | 7016 | 14745 | 1.00e-2 | 2.14e-2 |
BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 7.85e-3 |
BMI | BMI European | ETC | Locke | 2015 | NA | 234069 | 1.00e-3 | 1.96e-2 |
BMI | BMI European Men | MTC | Locke | 2015 | NA | 104666 | 1.00e-3 | 3.32e-3 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 8.61e-3 |
BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.95e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 1.33e-2 |
BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 3.46e-2 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 3.48e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.40e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.16e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 2.01e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.54e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 4.35e-2 |
BMI Smoking Adjusted | BMI Smoking Adjusted Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 4.79e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 5.00e-2 | 1.12e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 31800 | 1.00e-2 | 4.84e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 6.68e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 5.00e-2 | 3.09e-3 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density All | MTC | Medina-Gomez | 2018 | NA | 56284 | 1.00e-2 | 4.31e-2 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-2 | 6.89e-4 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-3 | 2.19e-2 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-4 | 9.18e-3 |
Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 1.00e-5 | 4.06e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 3.04e-2 |
Coronary Artery Disease | Coronary Artery Disease Additive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-3 | 4.83e-2 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 5.00e-2 | 1.18e-2 |
Coronary Artery Disease | Myocardial Infarction Additive Model | MTC | Nikpay | 2015 | 27509 | 99121 | 1.00e-3 | 2.34e-2 |
Diarrhoeal Disease | Diarrhea Age 2 | MTC | Bustamante | 2016 | 2855 | 2753 | 5.00e-2 | 4.53e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI Women | MTC | Chu | 2017 | NA | 7618 | 1.00e-2 | 4.51e-2 |
Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14668 | 5.00e-2 | 2.53e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 5.00e-2 | 7.13e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 1.00e-2 | 1.88e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 5.00e-2 | 2.01e-2 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 3.54e-3 |
Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-3 | 2.88e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation All | MTC | Chu | 2017 | NA | 11478 | 1.00e-2 | 4.43e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 5.00e-2 | 7.24e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 2.66e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 4.37e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 5.00e-2 | 4.94e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-3 | 4.37e-2 |
Educational Attainment | Education Years All | ETC | Okbay | 2016 | NA | 293723 | 5.00e-2 | 2.93e-2 |
Estimated Glomerular Filtration Rate | Chronic Kidney Disease Without Diabetes | MTC | Pattaro | 2016 | NA | 118448 | 5.00e-2 | 4.99e-2 |
Estimated Glomerular Filtration Rate | Serum Creatinine | MTC | Pattaro | 2016 | NA | 133413 | 5.00e-2 | 3.77e-2 |
Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.68e-2 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.04e-2 |
Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 8.12e-3 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.81e-2 |
Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.24e-2 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.10e-3 |
Facial Shape | Mod26 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.75e-3 |
Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.93e-2 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.65e-3 |
Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 5.31e-3 |
Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.90e-2 |
Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.81e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 1.00e-2 | 4.85e-2 |
Gestational Weight Gain | Early Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 8559 | 5.00e-2 | 3.97e-2 |
Insulin Secretion | Acute Insulin Response | MTC | Wood | 2017 | NA | 2087 | 1.00e-2 | 3.16e-2 |
Insulin Sensitivity Index | Model 2 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.66e-2 |
Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 1.85e-2 |
Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 4.48e-2 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 5.00e-2 | 1.69e-2 |
Intracerebral Hemorrhage | Lobar ICH | MTC | Woo | 2014 | 664 | 1481 | 1.00e-2 | 1.81e-3 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-2 | 2.70e-2 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-3 | 4.56e-3 |
Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 4.68e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 2.36e-2 |
Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-3 | 2.03e-2 |
Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-3 | 1.22e-2 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 2.36e-2 |
Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-4 | 4.79e-2 |
Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 1.00e-3 | 1.56e-2 |
Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-2 | 4.61e-2 |
TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 5.00e-2 | 3.14e-2 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.46e-2 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.39e-2 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-3 | 3.87e-2 |
Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 7.54e-3 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 4.48e-2 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 5.75e-3 |
Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-3 | 9.93e-4 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 3.56e-2 |
Pubertal Anthropometrics | Total Pubertal Height Increase Females | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 5.09e-3 |
Reproductive Behavior | Number Children Ever Born Female | MTC | Barban | 2016 | NA | 225230 | 1.00e-2 | 1.20e-2 |
Social Deprivation | Household Income | MTC | Hill | 2016 | NA | 112005 | 1.00e-4 | 1.23e-2 |
Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 5.00e-2 | 1.71e-2 |
Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 1.00e-4 | 3.82e-2 |
Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.90e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.70e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 2.58e-2 |
Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 4.37e-2 |
RHR | CAD Resting Heart Rate | ETC | Eppinga | 2016 | NA | 265046 | 1.00e-3 | 7.93e-3 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-3 | 2.97e-2 |
CEL | Celiac Disease | ETC | Trynka | 2011 | 12041 | 12228 | 1.00e-2 | 2.33e-3 |
Ambidextrousness | Ambidextrousness | ETC | Kovel | 2019 | 5324 | 325713 | 1.00e-2 | 9.63e-3 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 5.00e-2 | 1.76e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.65e-2 |
Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 1.69e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.79e-2 |
Sleep | Sleep duration | ETC | Jones | 2019 | NA | 85449 | 5.00e-2 | 4.32e-3 |
Facial attractiveness | Facial attractiveness of males, male raters | ETC | Hu | 2019 | NA | 1792 | 5.00e-2 | 3.54e-2 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 5.00e-2 | 4.38e-3 |
Obesity | Obesity, extreme obese children vs control adult | ETC | McKay | 2019 | 1456 | 6460 | 1.00e-2 | 1.43e-3 |
Body fat distribution | Body fat distribution-arm-fat-ratio-female | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 2.95e-2 |
Body fat distribution | Body fat distribution-arm-fat-ratio-male | ETC | Andersen | 2019 | NA | 116138 | 5.00e-2 | 2.10e-3 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-2 | 2.31e-2 |
Nonischemic cardiomyopathy | Nonischemic cardiomyopathy | ETC | Aragam | 2018 | 1816 | 388326 | 1.00e-3 | 2.29e-2 |
Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 3.90e-2 |
Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.76e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 4.25e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 3.37e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-4 | 3.87e-3 |
Na/C | Urinary sodium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218450 | 1.00e-5 | 3.79e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-2 | 1.11e-2 |
AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-3 | 1.11e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 2.14e-2 |
Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-3 | 2.14e-2 |
Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 4.25e-2 |
Medication use | Medication use (antimigraine preparations) | ETC | Wu Y | 2019 | 5,521 | 114,323 | 1.00e-5 | 2.58e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 5.00e-2 | 2.44e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 5.62e-3 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 3.79e-2 |
Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-4 | 2.74e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 5.00e-2 | 1.07e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 4.50e-2 |
Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-2 | 1.70e-2 |
Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 1.00e-3 | 8.58e-4 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.80e-4 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 7.72e-3 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-2 | 1.76e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 5.00e-2 | 1.52e-2 |
Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 5.00e-2 | 3.07e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 3.68e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 5.00e-2 | 2.89e-2 |
Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 5.00e-2 | 8.67e-3 |
Birth | Spontaneous preterm birth (preterm birth) | ETC | Liu X | 2019 | 4,775 | 60,148 | 1.00e-2 | 1.86e-2 |
Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 1.84e-2 |
Waist to hip ratio | Waist-hip ratio variance | ETC | Wang H | 2019 | NA | 347,134 | 5.00e-2 | 6.91e-4 |
Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 4.03e-2 |
Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 2.74e-2 |
Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 2.74e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 5.00e-2 | 3.54e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 1.93e-2 |
Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 1.00e-3 | 3.16e-2 |
Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 5.00e-2 | 4.52e-2 |
BMI by age | BMI at 1 year old | ETC | Helgeland O | 2019 | NA | 6,970 | 1.00e-2 | 3.59e-2 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 5.00e-2 | 9.91e-3 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 5.73e-4 |
BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 5.52e-4 |
Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 4.14e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 2.04e-2 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 8.92e-3 |
Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-3 | 4.66e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 5.00e-2 | 3.00e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 3.96e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 1.28e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 5.00e-2 | 2.94e-2 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-2 | 1.63e-3 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-3 | 9.71e-4 |
Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 1.14e-3 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.30e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.97e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.52e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.75e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 5.26e-7 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 2.02e-5 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 5.57e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 2.84e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 1.43e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 5.00e-2 | 1.31e-2 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 5.00e-2 | 7.44e-3 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 4.81e-2 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 2.16e-3 |
COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 5.00e-2 | 4.05e-4 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.